{"transactions":[{"id":4616503,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39261,"kind":"person","name":"Reid Laurence","position":1,"cik":"0001492749","reported_name":"Reid Laurence","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-11T23:51:38.000Z","date":"2026-09-09","kind":"purchase","planned":false,"acquired":true,"shares":117,"price":1.18,"value":138.06,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001193125-26-389550","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526389550/ownership.xml","form_type":"4"}},{"id":4616502,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39261,"kind":"person","name":"Reid Laurence","position":1,"cik":"0001492749","reported_name":"Reid Laurence","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-11T23:51:38.000Z","date":"2026-09-09","kind":"purchase","planned":false,"acquired":true,"shares":19883,"price":1.17,"value":23263.11,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.165 to $1.175. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request."}],"balance_after":19883,"source":{"system":"sec-edgar","filing":"0001193125-26-389550","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526389550/ownership.xml","form_type":"4"}},{"id":4614486,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39723,"kind":"person","name":"Wein Matthew","position":1,"cik":"0002009713","reported_name":"Wein Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-10T19:47:28.000Z","date":"2026-09-08","kind":"sale","planned":false,"acquired":false,"shares":358,"price":1.1584,"value":414.7072,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on each of April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":126133,"source":{"system":"sec-edgar","filing":"0001193125-26-387816","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009713/000119312526387816/ownership.xml","form_type":"4"}},{"id":4614481,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39529,"kind":"person","name":"Irish Jian","position":1,"cik":"0001995697","reported_name":"Irish Jian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-10T19:40:23.000Z","date":"2026-09-08","kind":"sale","planned":false,"acquired":false,"shares":2140,"price":1.1584,"value":2478.976,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":375393,"source":{"system":"sec-edgar","filing":"0001193125-26-387798","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1995697/000119312526387798/ownership.xml","form_type":"4"}},{"id":4614472,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39530,"kind":"person","name":"Wapnick Pamela","position":1,"cik":"0001995657","reported_name":"Wapnick Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-10T19:34:32.000Z","date":"2026-09-08","kind":"sale","planned":false,"acquired":false,"shares":1911,"price":1.1584,"value":2213.7024,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":206580,"source":{"system":"sec-edgar","filing":"0001193125-26-387786","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1995657/000119312526387786/ownership.xml","form_type":"4"}},{"id":741659,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39261,"kind":"person","name":"Reid Laurence","position":1,"cik":"0001492749","reported_name":"Reid Laurence","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T18:31:48.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":17400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date."}],"balance_after":17400,"derivative":{"exercise_price":1.23,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":17400},"source":{"system":"sec-edgar","filing":"0001193125-26-267272","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492749/000119312526267272/ownership.xml","form_type":"4"}},{"id":741473,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T18:23:03.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date."}],"balance_after":21000,"derivative":{"exercise_price":1.23,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001193125-26-267255","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000119312526267255/ownership.xml","form_type":"4"}},{"id":741424,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":24148,"kind":"person","name":"BJERKHOLT ERIC","position":1,"cik":"0001197350","reported_name":"BJERKHOLT ERIC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T17:49:03.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date."}],"balance_after":21000,"derivative":{"exercise_price":1.23,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001193125-26-267189","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1197350/000119312526267189/ownership.xml","form_type":"4"}},{"id":741117,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39146,"kind":"person","name":"Eckhardt Juergen","position":1,"cik":"0001857806","reported_name":"Eckhardt Juergen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T17:37:40.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date."}],"balance_after":21000,"derivative":{"exercise_price":1.23,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001193125-26-267170","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526267170/ownership.xml","form_type":"4"}},{"id":742572,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39530,"kind":"person","name":"Wapnick Pamela","position":1,"cik":"0001995657","reported_name":"Wapnick Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-10T15:23:47.000Z","date":"2026-06-05","kind":"sale","planned":false,"acquired":false,"shares":2884,"price":1.299,"value":3746.316,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":208491,"source":{"system":"sec-edgar","filing":"0001193125-26-265335","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526265335/ownership.xml","form_type":"4"}},{"id":742571,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39529,"kind":"person","name":"Irish Jian","position":1,"cik":"0001995697","reported_name":"Irish Jian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-06-10T15:21:46.000Z","date":"2026-06-05","kind":"sale","planned":false,"acquired":false,"shares":3737,"price":1.299,"value":4854.363,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,500 shares acquired under the Company's employee stock purchase plan (\"ESPP\") on May 29, 2026."}],"balance_after":377533,"source":{"system":"sec-edgar","filing":"0001193125-26-265332","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526265332/ownership.xml","form_type":"4"}},{"id":743386,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39723,"kind":"person","name":"Wein Matthew","position":1,"cik":"0002009713","reported_name":"Wein Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-06-10T15:19:56.000Z","date":"2026-06-05","kind":"sale","planned":false,"acquired":false,"shares":558,"price":1.299,"value":724.842,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on each of April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,500 shares acquired under the Company's employee stock purchase plan (\"ESPP\") on May 29, 2026."}],"balance_after":126491,"source":{"system":"sec-edgar","filing":"0001193125-26-265326","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009713/000119312526265326/ownership.xml","form_type":"4"}},{"id":815395,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39529,"kind":"person","name":"Irish Jian","position":1,"cik":"0001995697","reported_name":"Irish Jian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T18:11:59.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":276000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to this option shall vest and become exercisable on April 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":276000,"derivative":{"exercise_price":1.34,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":276000},"source":{"system":"sec-edgar","filing":"0001193125-26-141946","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526141946/ownership.xml","form_type":"4"}},{"id":815394,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39529,"kind":"person","name":"Irish Jian","position":1,"cik":"0001995697","reported_name":"Irish Jian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-04-03T18:11:59.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":46000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). 25% of the RSUs shall vest on June 5, 2027, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":379770,"source":{"system":"sec-edgar","filing":"0001193125-26-141946","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526141946/ownership.xml","form_type":"4"}},{"id":816999,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39723,"kind":"person","name":"Wein Matthew","position":1,"cik":"0002009713","reported_name":"Wein Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T18:00:49.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":68000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on April 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":68000,"derivative":{"exercise_price":1.34,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":68000},"source":{"system":"sec-edgar","filing":"0001193125-26-141914","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2009713/000119312526141914/ownership.xml","form_type":"4"}},{"id":816998,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39723,"kind":"person","name":"Wein Matthew","position":1,"cik":"0002009713","reported_name":"Wein Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-04-03T18:00:49.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). 25% of the RSUs shall vest on June 5, 2027, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":125549,"source":{"system":"sec-edgar","filing":"0001193125-26-141914","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009713/000119312526141914/ownership.xml","form_type":"4"}},{"id":815393,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39530,"kind":"person","name":"Wapnick Pamela","position":1,"cik":"0001995657","reported_name":"Wapnick Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T17:40:12.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":144000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on April 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":144000,"derivative":{"exercise_price":1.34,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":144000},"source":{"system":"sec-edgar","filing":"0001193125-26-141867","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526141867/ownership.xml","form_type":"4"}},{"id":815392,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39530,"kind":"person","name":"Wapnick Pamela","position":1,"cik":"0001995657","reported_name":"Wapnick Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-03T17:40:12.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). 25% of the RSUs shall vest on June 5, 2027, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":211375,"source":{"system":"sec-edgar","filing":"0001193125-26-141867","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526141867/ownership.xml","form_type":"4"}},{"id":852925,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39530,"kind":"person","name":"Wapnick Pamela","position":1,"cik":"0001995657","reported_name":"Wapnick Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-09T21:16:44.000Z","date":"2026-03-05","kind":"sale","planned":false,"acquired":false,"shares":1581,"price":1.6,"value":2529.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person."}],"balance_after":187375,"source":{"system":"sec-edgar","filing":"0001193125-26-098824","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526098824/ownership.xml","form_type":"4"}},{"id":853856,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39723,"kind":"person","name":"Wein Matthew","position":1,"cik":"0002009713","reported_name":"Wein Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-09T21:16:17.000Z","date":"2026-03-05","kind":"sale","planned":false,"acquired":false,"shares":482,"price":1.6,"value":771.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on each of April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":114549,"source":{"system":"sec-edgar","filing":"0001193125-26-098821","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009713/000119312526098821/ownership.xml","form_type":"4"}},{"id":852924,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39529,"kind":"person","name":"Irish Jian","position":1,"cik":"0001995697","reported_name":"Irish Jian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-09T21:15:57.000Z","date":"2026-03-05","kind":"sale","planned":false,"acquired":false,"shares":1607,"price":1.6,"value":2571.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person."}],"balance_after":333770,"source":{"system":"sec-edgar","filing":"0001193125-26-098820","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526098820/ownership.xml","form_type":"4"}},{"id":852923,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39529,"kind":"person","name":"Irish Jian","position":1,"cik":"0001995697","reported_name":"Irish Jian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-09T21:15:57.000Z","date":"2025-12-05","kind":"gift","planned":false,"acquired":false,"shares":228462,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 5, 2025, the Reporting Person transferred 114,231 and 114,231 shares of Issuer common stock to the Bruce Irish 2023 Irrevocable Trust FBO Jian Irish and Jian Irish 2023 Irrevocable Trust, respectively, for no consideration."}],"balance_after":335377,"source":{"system":"sec-edgar","filing":"0001193125-26-098820","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526098820/ownership.xml","form_type":"4"}},{"id":977261,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":72048,"kind":"person","name":"Thomas Brian C.","position":1,"cik":"0001996097","reported_name":"Thomas Brian C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-08T18:56:16.000Z","date":"2025-12-05","kind":"sale","planned":false,"acquired":false,"shares":3830,"price":1.7719,"value":6786.377,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person."}],"balance_after":2510960,"source":{"system":"sec-edgar","filing":"0001193125-25-310971","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312525310971/ownership.xml","form_type":"4"}},{"id":977832,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39723,"kind":"person","name":"Wein Matthew","position":1,"cik":"0002009713","reported_name":"Wein Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-12-08T18:51:33.000Z","date":"2025-12-05","kind":"sale","planned":false,"acquired":false,"shares":199,"price":1.7719,"value":352.6081,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person."}],"balance_after":115031,"source":{"system":"sec-edgar","filing":"0001193125-25-310958","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009713/000119312525310958/ownership.xml","form_type":"4"}},{"id":977260,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39530,"kind":"person","name":"Wapnick Pamela","position":1,"cik":"0001995657","reported_name":"Wapnick Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-08T18:49:50.000Z","date":"2025-12-05","kind":"sale","planned":false,"acquired":false,"shares":1576,"price":1.7719,"value":2792.5144,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person."}],"balance_after":188956,"source":{"system":"sec-edgar","filing":"0001193125-25-310953","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312525310953/ownership.xml","form_type":"4"}},{"id":977259,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39529,"kind":"person","name":"Irish Jian","position":1,"cik":"0001995697","reported_name":"Irish Jian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-08T18:38:21.000Z","date":"2025-12-05","kind":"sale","planned":false,"acquired":false,"shares":1602,"price":1.7719,"value":2838.5838,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person."}],"balance_after":563839,"source":{"system":"sec-edgar","filing":"0001193125-25-310937","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312525310937/ownership.xml","form_type":"4"}},{"id":984783,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":72048,"kind":"person","name":"Thomas Brian C.","position":1,"cik":"0001996097","reported_name":"Thomas Brian C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-02T00:34:10.000Z","date":"2025-09-05","kind":"sale","planned":false,"acquired":false,"shares":2701,"price":1.81,"value":4888.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the reporting person on April 1, 2024, and does not represent a volitional trade by the Reporting Person."}],"balance_after":2514790,"source":{"system":"sec-edgar","filing":"0001193125-25-304221","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312525304221/ownership.xml","form_type":"4"}},{"id":984782,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39530,"kind":"person","name":"Wapnick Pamela","position":1,"cik":"0001995657","reported_name":"Wapnick Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-02T00:32:32.000Z","date":"2025-12-01","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":1.6,"value":192000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares represent RSUs. 50% of the RSUs shall vest on December 5, 2026, with the remainder vesting on December 5, 2027, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":190532,"source":{"system":"sec-edgar","filing":"0001193125-25-304218","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312525304218/ownership.xml","form_type":"4"}},{"id":984781,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39530,"kind":"person","name":"Wapnick Pamela","position":1,"cik":"0001995657","reported_name":"Wapnick Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-02T00:32:32.000Z","date":"2025-09-05","kind":"sale","planned":false,"acquired":false,"shares":1576,"price":1.81,"value":2852.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units (\"RSUs\") granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person."}],"balance_after":70532,"source":{"system":"sec-edgar","filing":"0001193125-25-304218","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312525304218/ownership.xml","form_type":"4"}},{"id":984780,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39529,"kind":"person","name":"Irish Jian","position":1,"cik":"0001995697","reported_name":"Irish Jian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-02T00:28:00.000Z","date":"2025-12-01","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to this option shall vest and become exercisable on November 6, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":225000,"derivative":{"exercise_price":1.6,"expiration_date":"2035-11-30","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001193125-25-304212","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312525304212/ownership.xml","form_type":"4"}},{"id":984779,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39529,"kind":"person","name":"Irish Jian","position":1,"cik":"0001995697","reported_name":"Irish Jian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-02T00:28:00.000Z","date":"2025-12-01","kind":"grant","planned":false,"acquired":true,"shares":211000,"price":1.6,"value":337600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These shares represent RSUs. 50% of the RSUs shall vest on December 5, 2026, with the remainder vesting on December 5, 2027, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":565441,"source":{"system":"sec-edgar","filing":"0001193125-25-304212","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312525304212/ownership.xml","form_type":"4"}},{"id":984778,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39529,"kind":"person","name":"Irish Jian","position":1,"cik":"0001995697","reported_name":"Irish Jian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-02T00:28:00.000Z","date":"2025-12-01","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":1.6,"value":60000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These shares represent RSUs. 25% of the RSUs shall vest on December 5, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":354441,"source":{"system":"sec-edgar","filing":"0001193125-25-304212","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312525304212/ownership.xml","form_type":"4"}},{"id":984777,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39529,"kind":"person","name":"Irish Jian","position":1,"cik":"0001995697","reported_name":"Irish Jian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-02T00:28:00.000Z","date":"2025-09-05","kind":"sale","planned":false,"acquired":false,"shares":1602,"price":1.81,"value":2899.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units (\"RSUs\") granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,500 shares acquired under the Company's employee stock purchase plan (\"ESPP\") on May 30, 2025 and 1,500 shares acquired under the Company's ESPP on November 28, 2025."}],"balance_after":316941,"source":{"system":"sec-edgar","filing":"0001193125-25-304212","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312525304212/ownership.xml","form_type":"4"}},{"id":985271,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39723,"kind":"person","name":"Wein Matthew","position":1,"cik":"0002009713","reported_name":"Wein Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-12-01T23:37:12.000Z","date":"2025-12-01","kind":"grant","planned":false,"acquired":true,"shares":96000,"price":1.6,"value":153600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These shares represent RSUs. 50% of the RSUs shall vest on December 5, 2026, with the remainder vesting on December 5, 2027, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":115230,"source":{"system":"sec-edgar","filing":"0001193125-25-304177","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2009713/000119312525304177/ownership.xml","form_type":"4"}},{"id":985270,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39723,"kind":"person","name":"Wein Matthew","position":1,"cik":"0002009713","reported_name":"Wein Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-12-01T23:37:12.000Z","date":"2025-09-05","kind":"sale","planned":false,"acquired":false,"shares":199,"price":1.81,"value":360.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units (\"RSUs\") granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,359 shares acquired under the Company's employee stock purchase plan (\"ESPP\") on May 30, 2025 and 1,377 shares acquired under the Company's ESPP on November 28, 2025."}],"balance_after":19230,"source":{"system":"sec-edgar","filing":"0001193125-25-304177","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009713/000119312525304177/ownership.xml","form_type":"4"}},{"id":1051408,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39261,"kind":"person","name":"Reid Laurence","position":1,"cik":"0001492749","reported_name":"Reid Laurence","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-02T20:44:51.000Z","date":"2025-09-02","kind":"grant","planned":false,"acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33% of the shares subject to this option shall vest and become exercisable on September 2, 2026, with the remainder vesting in 24 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":42000,"derivative":{"exercise_price":1.82,"expiration_date":"2035-09-01","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0000950170-25-112535","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492749/000095017025112535/ownership.xml","form_type":"4"}},{"id":1112807,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39146,"kind":"person","name":"Eckhardt Juergen","position":1,"cik":"0001857806","reported_name":"Eckhardt Juergen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:43:11.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date."}],"balance_after":21000,"derivative":{"exercise_price":1.57,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000950170-25-085499","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017025085499/ownership.xml","form_type":"4"}},{"id":1113160,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:36:15.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date."}],"balance_after":21000,"derivative":{"exercise_price":1.57,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000950170-25-085488","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000095017025085488/ownership.xml","form_type":"4"}},{"id":1113072,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":24148,"kind":"person","name":"BJERKHOLT ERIC","position":1,"cik":"0001197350","reported_name":"BJERKHOLT ERIC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:33:13.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":8572,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date."}],"balance_after":8572,"derivative":{"exercise_price":1.57,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":8572},"source":{"system":"sec-edgar","filing":"0000950170-25-085483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1197350/000095017025085483/ownership.xml","form_type":"4"}},{"id":1118281,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39723,"kind":"person","name":"Wein Matthew","position":1,"cik":"0002009713","reported_name":"Wein Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-06-09T23:04:41.000Z","date":"2025-06-06","kind":"sale","planned":false,"acquired":false,"shares":199,"price":1.75,"value":348.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the reporting person's tax withholding obligations upon the vesting of certain restricted stock units granted to the reporting person on April 1, 2024, and does not represent a volitional trade by the reporting person."}],"balance_after":16693,"source":{"system":"sec-edgar","filing":"0000950170-25-083963","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009713/000095017025083963/ownership.xml","form_type":"4"}},{"id":1117237,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39530,"kind":"person","name":"Wapnick Pamela","position":1,"cik":"0001995657","reported_name":"Wapnick Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-06-09T22:54:26.000Z","date":"2025-06-06","kind":"sale","planned":false,"acquired":false,"shares":1576,"price":1.75,"value":2758.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the reporting person's tax withholding obligations upon the vesting of certain restricted stock units granted to the reporting person on April 1, 2024, and does not represent a volitional trade by the reporting person."}],"balance_after":72108,"source":{"system":"sec-edgar","filing":"0000950170-25-083949","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017025083949/ownership.xml","form_type":"4"}},{"id":1117238,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":72048,"kind":"person","name":"Thomas Brian C.","position":1,"cik":"0001996097","reported_name":"Thomas Brian C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-09T22:50:36.000Z","date":"2025-06-06","kind":"sale","planned":false,"acquired":false,"shares":10785,"price":1.75,"value":18873.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the reporting person's tax withholding obligations upon the vesting of certain restricted stock units granted to the reporting person on April 1, 2024, and does not represent a volitional trade by the reporting person."}],"balance_after":2517491,"source":{"system":"sec-edgar","filing":"0000950170-25-083947","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017025083947/ownership.xml","form_type":"4"}},{"id":1117236,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39529,"kind":"person","name":"Irish Jian","position":1,"cik":"0001995697","reported_name":"Irish Jian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-06-09T22:20:17.000Z","date":"2025-06-06","kind":"sale","planned":false,"acquired":false,"shares":6390,"price":1.75,"value":11182.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the reporting person's tax withholding obligations upon the vesting of certain restricted stock units granted to the reporting person on April 1, 2024, and does not represent a volitional trade by the reporting person."}],"balance_after":315543,"source":{"system":"sec-edgar","filing":"0000950170-25-083930","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017025083930/ownership.xml","form_type":"4"}},{"id":1117960,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-06-09T18:57:07.000Z","date":"2025-06-06","kind":"sale","planned":false,"acquired":false,"shares":5239,"price":1.75,"value":9168.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the reporting person's tax withholding obligations upon the vesting of certain restricted stock units granted to the reporting person on April 1, 2024, and does not represent a volitional trade by the reporting person."}],"balance_after":109135,"source":{"system":"sec-edgar","filing":"0000950170-25-083952","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000095017025083952/ownership.xml","form_type":"4"}},{"id":1178607,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39530,"kind":"person","name":"Wapnick Pamela","position":1,"cik":"0001995657","reported_name":"Wapnick Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-03T15:58:31.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":84000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on April 1, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":84000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":84000},"source":{"system":"sec-edgar","filing":"0000950170-25-050103","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017025050103/ownership.xml","form_type":"4"}},{"id":1178606,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39530,"kind":"person","name":"Wapnick Pamela","position":1,"cik":"0001995657","reported_name":"Wapnick Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-04-03T15:58:31.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). 25% of the RSUs shall vest on June 5, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":73684,"source":{"system":"sec-edgar","filing":"0000950170-25-050103","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017025050103/ownership.xml","form_type":"4"}},{"id":1178605,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":72048,"kind":"person","name":"Thomas Brian C.","position":1,"cik":"0001996097","reported_name":"Thomas Brian C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-03T15:58:17.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":196000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on April 1, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":196000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":196000},"source":{"system":"sec-edgar","filing":"0000950170-25-050102","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017025050102/ownership.xml","form_type":"4"}},{"id":1178604,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":72048,"kind":"person","name":"Thomas Brian C.","position":1,"cik":"0001996097","reported_name":"Thomas Brian C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-03T15:58:17.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). 25% of the RSUs shall vest on June 5, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":2528276,"source":{"system":"sec-edgar","filing":"0000950170-25-050102","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017025050102/ownership.xml","form_type":"4"}},{"id":1178603,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39529,"kind":"person","name":"Irish Jian","position":1,"cik":"0001995697","reported_name":"Irish Jian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-03T15:57:48.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to this option shall vest and become exercisable on April 1, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":140000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0000950170-25-050101","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017025050101/ownership.xml","form_type":"4"}},{"id":1178602,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39529,"kind":"person","name":"Irish Jian","position":1,"cik":"0001995697","reported_name":"Irish Jian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-04-03T15:57:48.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). 25% of the RSUs shall vest on June 5, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":321933,"source":{"system":"sec-edgar","filing":"0000950170-25-050101","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017025050101/ownership.xml","form_type":"4"}},{"id":1180223,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39723,"kind":"person","name":"Wein Matthew","position":1,"cik":"0002009713","reported_name":"Wein Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-03T15:57:30.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":22725,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option shall vest and become exercisable on April 1, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":22725,"derivative":{"exercise_price":1.32,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":22725},"source":{"system":"sec-edgar","filing":"0000950170-25-050100","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2009713/000095017025050100/ownership.xml","form_type":"4"}},{"id":1180222,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39723,"kind":"person","name":"Wein Matthew","position":1,"cik":"0002009713","reported_name":"Wein Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-03T15:57:30.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":21875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option shall vest and become exercisable on April 1, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":21875,"derivative":{"exercise_price":1.32,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":21875},"source":{"system":"sec-edgar","filing":"0000950170-25-050100","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2009713/000095017025050100/ownership.xml","form_type":"4"}},{"id":1180221,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39723,"kind":"person","name":"Wein Matthew","position":1,"cik":"0002009713","reported_name":"Wein Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-04-03T15:57:30.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":3775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares represent restricted stock units (\"RSUs\"). 25% of the RSUs shall vest on March 5, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":16892,"source":{"system":"sec-edgar","filing":"0000950170-25-050100","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2009713/000095017025050100/ownership.xml","form_type":"4"}},{"id":1180220,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39723,"kind":"person","name":"Wein Matthew","position":1,"cik":"0002009713","reported_name":"Wein Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-04-03T15:57:30.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":3650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). 25% of the RSUs shall vest on June 5, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":13117,"source":{"system":"sec-edgar","filing":"0000950170-25-050100","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009713/000095017025050100/ownership.xml","form_type":"4"}},{"id":1179668,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-03T11:56:20.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":84000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on April 1, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":84000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":84000},"source":{"system":"sec-edgar","filing":"0000950170-25-050098","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000095017025050098/ownership.xml","form_type":"4"}},{"id":1179667,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-04-03T11:56:20.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). 25% of the RSUs shall vest on June 5, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":114374,"source":{"system":"sec-edgar","filing":"0000950170-25-050098","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000095017025050098/ownership.xml","form_type":"4"}},{"id":1217772,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39723,"kind":"person","name":"Wein Matthew","position":1,"cik":"0002009713","reported_name":"Wein Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-03-07T21:38:13.000Z","date":"2025-03-05","kind":"sale","planned":false,"acquired":false,"shares":930,"price":1.8748,"value":1743.564,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the reporting person's tax withholding obligations upon the vesting of certain restricted stock units granted to the reporting person on April 1, 2024, and does not represent a volitional trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $1.85 to $1.90, inclusive. The reporting person undertakes to provide to Metagenomi, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":9467,"source":{"system":"sec-edgar","filing":"0000950170-25-035566","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009713/000095017025035566/ownership.xml","form_type":"4"}},{"id":1216750,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39530,"kind":"person","name":"Wapnick Pamela","position":1,"cik":"0001995657","reported_name":"Wapnick Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-07T21:36:31.000Z","date":"2025-03-05","kind":"sale","planned":false,"acquired":false,"shares":1808,"price":1.8748,"value":3389.6384,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the reporting person's tax withholding obligations upon the vesting of certain restricted stock units granted to the reporting person on April 1, 2024, and does not represent a volitional trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $1.85 to $1.90, inclusive. The reporting person undertakes to provide to Metagenomi, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":59684,"source":{"system":"sec-edgar","filing":"0000950170-25-035565","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017025035565/ownership.xml","form_type":"4"}},{"id":1281631,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":24148,"kind":"person","name":"BJERKHOLT ERIC","position":1,"cik":"0001197350","reported_name":"BJERKHOLT ERIC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-05T21:24:01.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33.33% of the shares subject to this option shall vest and become exercisable on February 3, 2026, with the remainder vesting in 24 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":42000,"derivative":{"exercise_price":2.51,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0000950170-25-014528","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1197350/000095017025014528/ownership.xml","form_type":"4"}},{"id":1340059,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39530,"kind":"person","name":"Wapnick Pamela","position":1,"cik":"0001995657","reported_name":"Wapnick Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-06T21:24:30.000Z","date":"2024-12-05","kind":"sale","planned":false,"acquired":false,"shares":1559,"price":1.86,"value":2899.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the reporting person's tax withholding obligations upon the vesting of certain restricted stock units granted to the reporting person on April 1, 2024, and does not represent a volitional trade by the reporting person."}],"balance_after":61492,"source":{"system":"sec-edgar","filing":"0000950170-24-134124","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024134124/ownership.xml","form_type":"4"}},{"id":1412490,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39530,"kind":"person","name":"Wapnick Pamela","position":1,"cik":"0001995657","reported_name":"Wapnick Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-06T21:14:54.000Z","date":"2024-09-05","kind":"sale","planned":false,"acquired":false,"shares":6265,"price":2.88,"value":18043.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold for the purpose of satisfying the reporting person's tax withholding obligations upon the vesting of certain restricted stock units granted to the reporting person on April 1, 2024, and does not represent a volitional trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions ranging from $2.80 to $2.96. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shars sold at each price."}],"balance_after":63051,"source":{"system":"sec-edgar","filing":"0000950170-24-104439","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024104439/ownership.xml","form_type":"4"}},{"id":1548421,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39529,"kind":"person","name":"Irish Jian","position":1,"cik":"0001995697","reported_name":"Irish Jian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-04T01:10:33.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":296308,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to this option shall vest and become exercisable on April 1, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":296308,"derivative":{"exercise_price":10.82,"expiration_date":"2034-03-31","underlying":"Common Stock","underlying_shares":296308},"source":{"system":"sec-edgar","filing":"0000950170-24-041571","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024041571/ownership.xml","form_type":"4"}},{"id":1548420,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39529,"kind":"person","name":"Irish Jian","position":1,"cik":"0001995697","reported_name":"Irish Jian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-04-04T01:10:33.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":70471,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). 25% of the RSUs shall vest on June 5, 2025, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":298933,"source":{"system":"sec-edgar","filing":"0000950170-24-041571","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024041571/ownership.xml","form_type":"4"}},{"id":1548419,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39146,"kind":"person","name":"Eckhardt Juergen","position":1,"cik":"0001857806","reported_name":"Eckhardt Juergen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-04T01:08:36.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":78636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33.33% of the shares subject to this option shall vest and become exercisable on April 1, 2025, with the remainder vesting in 24 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":78636,"derivative":{"exercise_price":10.82,"expiration_date":"2034-03-31","underlying":"Common Stock","underlying_shares":78636},"source":{"system":"sec-edgar","filing":"0000950170-24-041569","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024041569/ownership.xml","form_type":"4"}},{"id":1550514,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39723,"kind":"person","name":"Wein Matthew","position":1,"cik":"0002009713","reported_name":"Wein Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-04T00:57:27.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":43717,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on February 1, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":43717,"derivative":{"exercise_price":10.82,"expiration_date":"2034-03-31","underlying":"Common Stock","underlying_shares":43717},"source":{"system":"sec-edgar","filing":"0000950170-24-041545","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2009713/000095017024041545/ownership.xml","form_type":"4"}},{"id":1550513,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39723,"kind":"person","name":"Wein Matthew","position":1,"cik":"0002009713","reported_name":"Wein Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-04-04T00:57:27.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":10397,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). 25% of the RSUs shall vest on March 5, 2025, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":10397,"source":{"system":"sec-edgar","filing":"0000950170-24-041545","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009713/000095017024041545/ownership.xml","form_type":"4"}},{"id":1548418,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39530,"kind":"person","name":"Wapnick Pamela","position":1,"cik":"0001995657","reported_name":"Wapnick Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-04T00:52:11.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":291450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on September 18, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":291450,"derivative":{"exercise_price":10.82,"expiration_date":"2034-03-31","underlying":"Common Stock","underlying_shares":291450},"source":{"system":"sec-edgar","filing":"0000950170-24-041537","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024041537/ownership.xml","form_type":"4"}},{"id":1548417,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39530,"kind":"person","name":"Wapnick Pamela","position":1,"cik":"0001995657","reported_name":"Wapnick Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-04-04T00:52:11.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":69316,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). 25% of the RSUs shall vest on September 5, 2024, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":69316,"source":{"system":"sec-edgar","filing":"0000950170-24-041537","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024041537/ownership.xml","form_type":"4"}},{"id":1548416,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":92247,"kind":"person","name":"Bernales Sebastian","position":1,"cik":"0001995659","reported_name":"Bernales Sebastian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-04T00:44:30.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":78636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33.33% of the shares subject to this option shall vest and become exercisable on April 1, 2025, with the remainder vesting in 24 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":78636,"derivative":{"exercise_price":10.82,"expiration_date":"2034-03-31","underlying":"Common Stock","underlying_shares":78636},"source":{"system":"sec-edgar","filing":"0000950170-24-041521","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024041521/ownership.xml","form_type":"4"}},{"id":1548415,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":92246,"kind":"person","name":"Harnest Simon","position":1,"cik":"0001995660","reported_name":"Harnest Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-04T00:40:58.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":48575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on April 1, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":48575,"derivative":{"exercise_price":10.82,"expiration_date":"2034-03-31","underlying":"Common Stock","underlying_shares":48575},"source":{"system":"sec-edgar","filing":"0000950170-24-041515","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024041515/ownership.xml","form_type":"4"}},{"id":1548414,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":92246,"kind":"person","name":"Harnest Simon","position":1,"cik":"0001995660","reported_name":"Harnest Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-04-04T00:40:58.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":11552,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). 25% of the RSUs shall vest on June 5, 2025, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":122664,"source":{"system":"sec-edgar","filing":"0000950170-24-041515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024041515/ownership.xml","form_type":"4"}},{"id":1548413,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":92245,"kind":"person","name":"Delaney Simren","position":1,"cik":"0001995684","reported_name":"Delaney Simren","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-04T00:18:18.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":29145,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on April 1, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":29145,"derivative":{"exercise_price":10.82,"expiration_date":"2034-03-31","underlying":"Common Stock","underlying_shares":29145},"source":{"system":"sec-edgar","filing":"0000950170-24-041483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024041483/ownership.xml","form_type":"4"}},{"id":1548412,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":92245,"kind":"person","name":"Delaney Simren","position":1,"cik":"0001995684","reported_name":"Delaney Simren","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-04-04T00:18:18.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":6931,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). 25% of the RSUs shall vest on June 5, 2025, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":93892,"source":{"system":"sec-edgar","filing":"0000950170-24-041483","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024041483/ownership.xml","form_type":"4"}},{"id":1549166,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-04T00:11:52.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":78636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33.33% of the shares subject to this option shall vest and become exercisable on April 1, 2025, with the remainder vesting in 24 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":78636,"derivative":{"exercise_price":10.82,"expiration_date":"2034-03-31","underlying":"Common Stock","underlying_shares":78636},"source":{"system":"sec-edgar","filing":"0000950170-24-041471","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000095017024041471/ownership.xml","form_type":"4"}},{"id":1548406,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":72048,"kind":"person","name":"Thomas Brian C.","position":1,"cik":"0001996097","reported_name":"Thomas Brian C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-04T00:00:22.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":500323,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on April 1, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":500323,"derivative":{"exercise_price":10.82,"expiration_date":"2034-03-31","underlying":"Common Stock","underlying_shares":500323},"source":{"system":"sec-edgar","filing":"0000950170-24-041449","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024041449/ownership.xml","form_type":"4"}},{"id":1548405,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":72048,"kind":"person","name":"Thomas Brian C.","position":1,"cik":"0001996097","reported_name":"Thomas Brian C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-04-04T00:00:22.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":118992,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). 25% of the RSUs shall vest on June 5, 2025, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":2496276,"source":{"system":"sec-edgar","filing":"0000950170-24-041449","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024041449/ownership.xml","form_type":"4"}},{"id":1549655,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":92271,"kind":"person","name":"Borges Luis","position":1,"cik":"0001684015","reported_name":"Borges Luis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-03T20:59:50.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":291450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on August 1, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":291450,"derivative":{"exercise_price":10.82,"expiration_date":"2034-03-31","underlying":"Common Stock","underlying_shares":291450},"source":{"system":"sec-edgar","filing":"0000950170-24-041551","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1684015/000095017024041551/ownership.xml","form_type":"4"}},{"id":1549654,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":92271,"kind":"person","name":"Borges Luis","position":1,"cik":"0001684015","reported_name":"Borges Luis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-04-03T20:59:50.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":69316,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). 25% of the RSUs shall vest on September 5, 2024, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":69316,"source":{"system":"sec-edgar","filing":"0000950170-24-041551","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1684015/000095017024041551/ownership.xml","form_type":"4"}},{"id":1549773,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-03T20:47:43.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":242875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on April 1, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":242875,"derivative":{"exercise_price":10.82,"expiration_date":"2034-03-31","underlying":"Common Stock","underlying_shares":242875},"source":{"system":"sec-edgar","filing":"0000950170-24-041527","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000095017024041527/ownership.xml","form_type":"4"}},{"id":1549772,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-04-03T20:47:43.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":57763,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). 25% of the RSUs shall vest on June 5, 2025, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":100374,"source":{"system":"sec-edgar","filing":"0000950170-24-041527","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000095017024041527/ownership.xml","form_type":"4"}},{"id":1640681,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES B-1 PREFERRED STOCK","published_at":"2024-02-16T01:38:42.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":691760,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":691760},"source":{"system":"sec-edgar","filing":"0001209191-24-003423","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919124003423/doc4.xml","form_type":"4"}},{"id":1640680,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES B PREFERRED STOCK","published_at":"2024-02-16T01:38:42.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":147415,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":147415},"source":{"system":"sec-edgar","filing":"0001209191-24-003423","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919124003423/doc4.xml","form_type":"4"}},{"id":1640679,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2024-02-16T01:38:42.000Z","date":"2024-02-13","kind":"purchase","planned":false,"acquired":true,"shares":800000,"price":15,"value":12000000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents a purchase from the underwriters in the Issuer's initial public offering."}],"balance_after":1739175,"source":{"system":"sec-edgar","filing":"0001209191-24-003423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919124003423/doc4.xml","form_type":"4"}},{"id":1640678,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2024-02-16T01:38:42.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":true,"shares":839175,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."}],"balance_after":939175,"source":{"system":"sec-edgar","filing":"0001209191-24-003423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919124003423/doc4.xml","form_type":"4"}},{"id":1640677,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2024-02-16T01:38:42.000Z","date":"2024-02-09","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":10.25,"value":1025000.0,"ownership":{"direct":true},"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001209191-24-003423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919124003423/doc4.xml","form_type":"4"}},{"id":1641383,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":890671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":509855},"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1641382,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":1030086,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":589662},"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1641381,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-4 Convertible Preferred Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":2062387,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series A-4 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series A-4 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series A-4 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1180592},"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1641380,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":3093580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's Initial Public Offering (\"IPO\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's Initial Public Offering (\"IPO\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's Initial Public Offering (\"IPO\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1770888},"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1641379,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":true,"shares":509855,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":4050997,"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1641378,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":true,"shares":589662,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":3541142,"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1641377,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":true,"shares":1180592,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series A-4 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":2951480,"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1641376,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":true,"shares":1770888,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's Initial Public Offering (\"IPO\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":1770888,"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1642532,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":92247,"kind":"person","name":"Bernales Sebastian","position":1,"cik":"0001995659","reported_name":"Bernales Sebastian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2024-02-14T21:29:38.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":106627,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Humboldt Fund I, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's Common Stock (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock at a ratio of 1 to 1.74692 effected by the Issuer on January 26, 2024). The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's Common Stock (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock at a ratio of 1 to 1.74692 effected by the Issuer on January 26, 2024). The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's Common Stock (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock at a ratio of 1 to 1.74692 effected by the Issuer on January 26, 2024). The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held directly by Humboldt Fund I, LP. Humboldt Fund I, LP is solely managed by Humboldt Capital, LLC, which is in turn managed by Sebastian Bernales, Francisco Dopazo and Benjamin Quiroga. Each of Mr. Bernales, Dopazo and Quiroga expressly disclaims beneficial ownership of the securities held by Humboldt Fund I, LP, except to the extent of his pecuniary interest in such securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":61037},"source":{"system":"sec-edgar","filing":"0000950170-24-015269","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024015269/ownership.xml","form_type":"4"}},{"id":1642531,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":92247,"kind":"person","name":"Bernales Sebastian","position":1,"cik":"0001995659","reported_name":"Bernales Sebastian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-02-14T21:29:38.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":1143905,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Humboldt Fund I, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's Common Stock (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock at a ratio of 1 to 1.74692 effected by the Issuer on January 26, 2024). The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's Common Stock (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock at a ratio of 1 to 1.74692 effected by the Issuer on January 26, 2024). The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's Common Stock (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock at a ratio of 1 to 1.74692 effected by the Issuer on January 26, 2024). The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held directly by Humboldt Fund I, LP. Humboldt Fund I, LP is solely managed by Humboldt Capital, LLC, which is in turn managed by Sebastian Bernales, Francisco Dopazo and Benjamin Quiroga. Each of Mr. Bernales, Dopazo and Quiroga expressly disclaims beneficial ownership of the securities held by Humboldt Fund I, LP, except to the extent of his pecuniary interest in such securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":654816},"source":{"system":"sec-edgar","filing":"0000950170-24-015269","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024015269/ownership.xml","form_type":"4"}},{"id":1642530,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":92247,"kind":"person","name":"Bernales Sebastian","position":1,"cik":"0001995659","reported_name":"Bernales Sebastian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-4 Preferred Stock","published_at":"2024-02-14T21:29:38.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":2062387,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Humboldt Fund I, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's Common Stock (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock at a ratio of 1 to 1.74692 effected by the Issuer on January 26, 2024). The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's Common Stock (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock at a ratio of 1 to 1.74692 effected by the Issuer on January 26, 2024). The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's Common Stock (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock at a ratio of 1 to 1.74692 effected by the Issuer on January 26, 2024). The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held directly by Humboldt Fund I, LP. Humboldt Fund I, LP is solely managed by Humboldt Capital, LLC, which is in turn managed by Sebastian Bernales, Francisco Dopazo and Benjamin Quiroga. Each of Mr. Bernales, Dopazo and Quiroga expressly disclaims beneficial ownership of the securities held by Humboldt Fund I, LP, except to the extent of his pecuniary interest in such securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1180592},"source":{"system":"sec-edgar","filing":"0000950170-24-015269","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024015269/ownership.xml","form_type":"4"}},{"id":1642529,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":92247,"kind":"person","name":"Bernales Sebastian","position":1,"cik":"0001995659","reported_name":"Bernales Sebastian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-4 Preferred Stock","published_at":"2024-02-14T21:29:38.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":423469,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's Common Stock (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock at a ratio of 1 to 1.74692 effected by the Issuer on January 26, 2024). The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's Common Stock (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock at a ratio of 1 to 1.74692 effected by the Issuer on January 26, 2024). The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's Common Stock (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock at a ratio of 1 to 1.74692 effected by the Issuer on January 26, 2024). The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":242410},"source":{"system":"sec-edgar","filing":"0000950170-24-015269","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024015269/ownership.xml","form_type":"4"}},{"id":1642528,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":92247,"kind":"person","name":"Bernales Sebastian","position":1,"cik":"0001995659","reported_name":"Bernales Sebastian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-3 Preferred Stock","published_at":"2024-02-14T21:29:38.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":119699,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's Common Stock (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock at a ratio of 1 to 1.74692 effected by the Issuer on January 26, 2024). The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's Common Stock (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock at a ratio of 1 to 1.74692 effected by the Issuer on January 26, 2024). The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's Common Stock (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock at a ratio of 1 to 1.74692 effected by the Issuer on January 26, 2024). The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":68520},"source":{"system":"sec-edgar","filing":"0000950170-24-015269","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024015269/ownership.xml","form_type":"4"}},{"id":1642527,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":92247,"kind":"person","name":"Bernales Sebastian","position":1,"cik":"0001995659","reported_name":"Bernales Sebastian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2024-02-14T21:29:38.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":353005,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's Common Stock (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock at a ratio of 1 to 1.74692 effected by the Issuer on January 26, 2024). The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's Common Stock (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock at a ratio of 1 to 1.74692 effected by the Issuer on January 26, 2024). The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's Common Stock (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock at a ratio of 1 to 1.74692 effected by the Issuer on January 26, 2024). The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":202074},"source":{"system":"sec-edgar","filing":"0000950170-24-015269","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024015269/ownership.xml","form_type":"4"}},{"id":1642526,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":92247,"kind":"person","name":"Bernales Sebastian","position":1,"cik":"0001995659","reported_name":"Bernales Sebastian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-14T21:29:38.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":true,"shares":1896445,"ownership":{"direct":false,"nature":"By Humboldt Fund I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's Common Stock (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock at a ratio of 1 to 1.74692 effected by the Issuer on January 26, 2024). The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held directly by Humboldt Fund I, LP. Humboldt Fund I, LP is solely managed by Humboldt Capital, LLC, which is in turn managed by Sebastian Bernales, Francisco Dopazo and Benjamin Quiroga. Each of Mr. Bernales, Dopazo and Quiroga expressly disclaims beneficial ownership of the securities held by Humboldt Fund I, LP, except to the extent of his pecuniary interest in such securities."}],"balance_after":1896445,"source":{"system":"sec-edgar","filing":"0000950170-24-015269","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024015269/ownership.xml","form_type":"4"}}],"next_cursor":"2024-02-14T21:29:38.000000Z,1642526"}